Pathogen-related signal transduction pathways of dendritic cells: Perspectives for cancer immunotherapy

Tomonori Kato, Yasuji Ueda, Hiroaki Kinoh, Kaori Tsukada, Tomohiko Ichikawa, Yoshikazu Yonemitsu

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Dendritic cells (DCs) play a crucial role in translating innate to adaptive immunity. DC-based cancer immunotherapy has been under evaluation; however, its clinical benefits remain limited. A better understanding of DCs is, therefore, needed to improve clinical outcomes. Toll-like receptors (TLRs) were initially identified as molecules that recognize and bind pathogen-associated molecular patterns (PAMPs) leading to DC maturation. The TLR signaling pathway leads to the activation of NF-κB, which initiates the transcription of proinflammatory cytokine genes. As the sensors of RNA viruses in the cellular cytoplasm, RNA helicases containing retinoic acid-inducible gene-I (RIG-I) have been shown to recognize the viral RNA genome, and recent studies have demonstrated that these helicases strongly induce the upregulation of type I interferons. We recently demonstrated that RNA viruses strongly activated DCs, and this finding is expected to aid in the development of improved DC-based cancer immunotherapy. We then proposed DC-based "immunostimulatory RNA virotherapy" as a novel therapeutic approach. The janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) are key molecules in a major signaling pathway for modulating DC function; suppressors of cytokine signaling (SOCSs) inhibit this pathway. Some recent studies have suggested that the suppression of SOCS family proteins in DCs modulates immune responses, including anticancer immunity. Here, we review recent progress in the elucidation of the mechanisms of signal transduction pathways in DCs; it is hoped that such investigations will eventually lead to a variety of DC-based cancer immunotherapies.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalCurrent Signal Transduction Therapy
Volume3
Issue number2
DOIs
Publication statusPublished - May 1 2008
Externally publishedYes

Fingerprint

Immunotherapy
Dendritic Cells
Signal Transduction
Neoplasms
Toll-Like Receptors
RNA Viruses
Suppressor of Cytokine Signaling Proteins
RNA Helicases
Cytokines
Janus Kinases
Interferon Type I
Viral Genome
Viral RNA
Adaptive Immunity
Tretinoin
Transducers
Genes
Immunity
Cytoplasm
Up-Regulation

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Pharmacology (medical)

Cite this

Pathogen-related signal transduction pathways of dendritic cells : Perspectives for cancer immunotherapy. / Kato, Tomonori; Ueda, Yasuji; Kinoh, Hiroaki; Tsukada, Kaori; Ichikawa, Tomohiko; Yonemitsu, Yoshikazu.

In: Current Signal Transduction Therapy, Vol. 3, No. 2, 01.05.2008, p. 133-137.

Research output: Contribution to journalReview article

Kato, Tomonori ; Ueda, Yasuji ; Kinoh, Hiroaki ; Tsukada, Kaori ; Ichikawa, Tomohiko ; Yonemitsu, Yoshikazu. / Pathogen-related signal transduction pathways of dendritic cells : Perspectives for cancer immunotherapy. In: Current Signal Transduction Therapy. 2008 ; Vol. 3, No. 2. pp. 133-137.
@article{876c318d70e04c72b8b58114472bd08b,
title = "Pathogen-related signal transduction pathways of dendritic cells: Perspectives for cancer immunotherapy",
abstract = "Dendritic cells (DCs) play a crucial role in translating innate to adaptive immunity. DC-based cancer immunotherapy has been under evaluation; however, its clinical benefits remain limited. A better understanding of DCs is, therefore, needed to improve clinical outcomes. Toll-like receptors (TLRs) were initially identified as molecules that recognize and bind pathogen-associated molecular patterns (PAMPs) leading to DC maturation. The TLR signaling pathway leads to the activation of NF-κB, which initiates the transcription of proinflammatory cytokine genes. As the sensors of RNA viruses in the cellular cytoplasm, RNA helicases containing retinoic acid-inducible gene-I (RIG-I) have been shown to recognize the viral RNA genome, and recent studies have demonstrated that these helicases strongly induce the upregulation of type I interferons. We recently demonstrated that RNA viruses strongly activated DCs, and this finding is expected to aid in the development of improved DC-based cancer immunotherapy. We then proposed DC-based {"}immunostimulatory RNA virotherapy{"} as a novel therapeutic approach. The janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) are key molecules in a major signaling pathway for modulating DC function; suppressors of cytokine signaling (SOCSs) inhibit this pathway. Some recent studies have suggested that the suppression of SOCS family proteins in DCs modulates immune responses, including anticancer immunity. Here, we review recent progress in the elucidation of the mechanisms of signal transduction pathways in DCs; it is hoped that such investigations will eventually lead to a variety of DC-based cancer immunotherapies.",
author = "Tomonori Kato and Yasuji Ueda and Hiroaki Kinoh and Kaori Tsukada and Tomohiko Ichikawa and Yoshikazu Yonemitsu",
year = "2008",
month = "5",
day = "1",
doi = "10.2174/157436208784223116",
language = "English",
volume = "3",
pages = "133--137",
journal = "Current Signal Transduction Therapy",
issn = "1574-3624",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Pathogen-related signal transduction pathways of dendritic cells

T2 - Perspectives for cancer immunotherapy

AU - Kato, Tomonori

AU - Ueda, Yasuji

AU - Kinoh, Hiroaki

AU - Tsukada, Kaori

AU - Ichikawa, Tomohiko

AU - Yonemitsu, Yoshikazu

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Dendritic cells (DCs) play a crucial role in translating innate to adaptive immunity. DC-based cancer immunotherapy has been under evaluation; however, its clinical benefits remain limited. A better understanding of DCs is, therefore, needed to improve clinical outcomes. Toll-like receptors (TLRs) were initially identified as molecules that recognize and bind pathogen-associated molecular patterns (PAMPs) leading to DC maturation. The TLR signaling pathway leads to the activation of NF-κB, which initiates the transcription of proinflammatory cytokine genes. As the sensors of RNA viruses in the cellular cytoplasm, RNA helicases containing retinoic acid-inducible gene-I (RIG-I) have been shown to recognize the viral RNA genome, and recent studies have demonstrated that these helicases strongly induce the upregulation of type I interferons. We recently demonstrated that RNA viruses strongly activated DCs, and this finding is expected to aid in the development of improved DC-based cancer immunotherapy. We then proposed DC-based "immunostimulatory RNA virotherapy" as a novel therapeutic approach. The janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) are key molecules in a major signaling pathway for modulating DC function; suppressors of cytokine signaling (SOCSs) inhibit this pathway. Some recent studies have suggested that the suppression of SOCS family proteins in DCs modulates immune responses, including anticancer immunity. Here, we review recent progress in the elucidation of the mechanisms of signal transduction pathways in DCs; it is hoped that such investigations will eventually lead to a variety of DC-based cancer immunotherapies.

AB - Dendritic cells (DCs) play a crucial role in translating innate to adaptive immunity. DC-based cancer immunotherapy has been under evaluation; however, its clinical benefits remain limited. A better understanding of DCs is, therefore, needed to improve clinical outcomes. Toll-like receptors (TLRs) were initially identified as molecules that recognize and bind pathogen-associated molecular patterns (PAMPs) leading to DC maturation. The TLR signaling pathway leads to the activation of NF-κB, which initiates the transcription of proinflammatory cytokine genes. As the sensors of RNA viruses in the cellular cytoplasm, RNA helicases containing retinoic acid-inducible gene-I (RIG-I) have been shown to recognize the viral RNA genome, and recent studies have demonstrated that these helicases strongly induce the upregulation of type I interferons. We recently demonstrated that RNA viruses strongly activated DCs, and this finding is expected to aid in the development of improved DC-based cancer immunotherapy. We then proposed DC-based "immunostimulatory RNA virotherapy" as a novel therapeutic approach. The janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) are key molecules in a major signaling pathway for modulating DC function; suppressors of cytokine signaling (SOCSs) inhibit this pathway. Some recent studies have suggested that the suppression of SOCS family proteins in DCs modulates immune responses, including anticancer immunity. Here, we review recent progress in the elucidation of the mechanisms of signal transduction pathways in DCs; it is hoped that such investigations will eventually lead to a variety of DC-based cancer immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=54949124968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949124968&partnerID=8YFLogxK

U2 - 10.2174/157436208784223116

DO - 10.2174/157436208784223116

M3 - Review article

AN - SCOPUS:54949124968

VL - 3

SP - 133

EP - 137

JO - Current Signal Transduction Therapy

JF - Current Signal Transduction Therapy

SN - 1574-3624

IS - 2

ER -